In late March, National Foundation for Celiac Awareness (NFCA) President and CEO Alice Bast and Director of Healthcare Initiatives Kristin Voorhees traveled to New York City for the Development of Therapies for Celiac Disease Conference, which was hosted by the Celiac Disease Center at Columbia University. There, renowned celiac disease experts and researchers shared research findings and their implications for people living with celiac disease.
Now, one of the studies discussed at the conference is being shared across the web. Researchers have discovered that a human protein, called elafin, may protect against the autoimmune response seen in people with celiac disease. The researchers developed a probiotic bacterium which was able to get elafin straight to the gut of mice.
While more research on elafin and its potential for treating celiac disease is needed, it is certainly promising new information for the celiac disease community. To learn more about the story, visit Science 2.0.
The NFCA team will keep you posted on more information as it becomes available. Stay up-to-date on research news and opportunities to become involved by signing up for NFCA’s Research Opt-In.